Conventional and microfluidic methods: Design and optimization of lipid-polymeric hybrid nanoparticles for gene therapy
Drug Delivery and Translational Research · 2025
DOI: 10.1007/s13346-024-01644-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2025. Verfasst von Daniel González-García und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering and Pharmaceutical Technology, Universidad de La Laguna, La Laguna, 38200, Spain. Hauptthemen laut MEDLINE: Nanoparticles, Genetic Therapy, Lipids. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad de la Laguna.
Abstract (Originalsprache)
Gene therapy holds significant promise as a therapeutic approach for addressing a diverse range of diseases through the suppression of overexpressed proteins and the restoration of impaired cell functions. Developing a nanocarrier that can efficiently load and release genetic material into cells remains a challenge. The primary goal of this study is to develop formulations aimed to enhance the therapeutic potential of GapmeRs through technological approaches. To this end, lipid-polymeric hybrid nanoparticles (LPHNPs) with PLGA, DC-cholesterol, and DOPE-mPEG 2000 were produced by conventional single-step nanoprecipitation (SSN) and microfluidic (MF) methods. The optimized nanoparticles by SSN have a size of 149.9 ± 18.07 nm, a polydispersity index (PdI) of 0.23 ± 0.02, and a zeta potential of (ZP) of 29.34 ± 2.44 mV, while by MF the size was 179.8 ± 6.3, a PdI of 0.24 ± 0.01, and a ZP of 32.25 ± 1.36 mV. Furthermore, LPHNPs prepared with GapmeR-protamine by both methods exhibit a high encapsulation efficiency of approximately 90%. The encapsulated GapmeR is completely released in 24 h. The LPHNP suspensions are stable for up to 6 h in 10% FBS at pH 5.4 and 7.4. By contrast, LPHNPs remain stable in suspension in 4.5% albumin at pH 7.4 for 24 h. Additionally, LPHNPs were successfully freeze-dried using trehalose in the range of 2.5-5% as cryoprotectant The LPHNPs produced by MF and SSN increase, 6 and 12 fold respectively, GapmeR cell uptake, and both of them reduce by 60–70% expression of Tob1 in 48 h.Our study demonstrates the efficacy of the developed LPHNPs as carriers for oligonucleotide delivery, offering valuable insights for their scale up production from a conventional bulk methodology to a high-throughput microfluidic technology. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical Engineering and Pharmaceutical Technology, Universidad de La Laguna, La Laguna, 38200, Spain.
- Institute of Biomedical Technologies (ITB), Center for Biomedical Research of the Canary Islands (CIBICAN), Universidad de La Laguna, La Laguna, 38200, Spain.
- Department of Basic Medical Sciences, Universidad de La Laguna, La Laguna, 38200, Spain.
- Department of Chemical Engineering and Pharmaceutical Technology, Universidad de La Laguna, La Laguna, 38200, Spain. pgarciag@ull.edu.es.
- Institute of Biomedical Technologies (ITB), Center for Biomedical Research of the Canary Islands (CIBICAN), Universidad de La Laguna, La Laguna, 38200, Spain. pgarciag@ull.edu.es.
- Department of Chemical Engineering and Pharmaceutical Technology, Universidad de La Laguna, La Laguna, 38200, Spain. adelgado@ull.edu.es.
ORCID-Profile: Daniel González-García, Olga Tapia, Carmen Évora, Patricia García-García, Araceli Delgado
Förderung
- Universidad de la Laguna
Zitieren
APA
González-García, D., Tapia, O., Évora, C., García-García, P., & Delgado, A. (2025). Conventional and microfluidic methods: Design and optimization of lipid-polymeric hybrid nanoparticles for gene therapy. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01644-4
Vancouver
González-García D, Tapia O, Évora C, García-García P, Delgado A. Conventional and microfluidic methods: Design and optimization of lipid-polymeric hybrid nanoparticles for gene therapy. Drug Delivery and Translational Research. 2025. doi:10.1007/s13346-024-01644-4
BibTeX
@article{GonzlezGarca2025,
author = {González-García, Daniel and Tapia, Olga and Évora, Carmen and García-García, Patricia and Delgado, Araceli},
title = {Conventional and microfluidic methods: Design and optimization of lipid-polymeric hybrid nanoparticles for gene therapy},
journal = {Drug Delivery and Translational Research},
year = {2025},
doi = {10.1007/s13346-024-01644-4}
}
EUVIMED